Keros Therapeutics, Inc. has revealed its financial results for the last period, showcasing significant changes in various metrics. The company reported a net loss of $17.8 million, or $0.63 per share, for the last period, compared to a net loss of $14.2 million, or $0.41 per share, for the same period last year.
Research and development expenses amounted to $15.9 million for the last period, up from $12.6 million for the comparative period. General and administrative expenses also increased to $4.2 million for the last period from $3.5 million for the same period last year.
Keros Therapeutics, Inc. ended the last period with cash, cash equivalents, and marketable securities totaling $185.3 million, compared to $205.9 million at the end of the same period last year.
The company's lead product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis. Meanwhile, KER-012 is being developed for the treatment of pulmonary arterial hypertension and cardiovascular disorders, and KER-065 is being developed for the treatment of obesity and neuromuscular diseases.
Today the company's shares have moved -3.0% to a price of $66.94. For more information, read the company's full 8-K submission here.
